Seqirus a business of CSL Limited presented findings from a new observational safety study conducted in the U.S. that found no unexpected adverse pregnancy outcomes in pregnant people who were vaccinated with the company's cell-based quadrivalent seasonal influenza vaccine (QIVc) during pregnancy. These data were presented at the Infectious Diseases Society for Obstetrics and Gynecology (IDSOG) Meeting on July 30, 2021. The prospective observational cohort study evaluated pregnancy outcomes and events of interest in the fetus or infant following vaccination with QIVc during any trimester. The findings from this study were reviewed by an independent Scientific Advisory Committee (SAC). Pregnant people are considered an at-risk population for influenza. Changes that occur in the immune system, heart and lungs during pregnancy can make those who are pregnant, and those who are up to two weeks postpartum, more prone to severe illness or complications from influenza. Influenza vaccination is the best way to prevent influenza and the Centers for Disease Control and Prevention (CDC) recommends seasonal influenza vaccine every year as the best way to prevent influenza for everyone six months of age and above who do not have contraindications. This recommendation extends to pregnant people as well. These clinical data are an addition to a growing body of evidence supporting the safety and utility of cell-based influenza vaccines like QIVc. The cell-based influenza vaccine, marketed in the U.S. as FLUCELVAX® QUADRIVALENT, is approved in the U.S. for use for the prevention of influenza disease in people two years and older and is currently under review with the U.S. Food and Drug Administration (FDA) for an expanded age indication for children as young as six months of age. QIVc utilizes a cell-based influenza vaccine manufacturing process, an alternative to traditional egg-based manufacturing.6 Cell-based influenza vaccines are designed to produce an exact match to those selected by the World Health Organization. Cell-based influenza vaccine technology may offer additional advantages over the standard influenza manufacturing process, including being more scalable and offering faster production in the event of an influenza pandemic. In the U.S., Seqirus operates a cell-based manufacturing facility in Holly Springs, North Carolina, purpose-built in partnership with the Biomedical Advanced Research and Development Authority (BARDA) to increase cell-based vaccine manufacturing capacity and combat pandemic influenza threats. Last year, Seqirus announced plans to build a new, world-class cell-based manufacturing facility in Australia, which will be the only cell-based influenza vaccine manufacturing facility in the Southern Hemisphere.